Moe SM, Drüeke T, Lameire N, Eknoyan G (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 14(1):3–12

Article  PubMed  Google Scholar 

Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913–921

Article  PubMed  CAS  Google Scholar 

Tentori F, Wang M, Biener BA et al (2015) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol 10(1):98–109

Article  PubMed  CAS  Google Scholar 

Kalantar-Zadeh K, Kuwae N, Regidor DL et al (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771–780

Article  PubMed  CAS  Google Scholar 

Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transpl 26:1948–1955

Article  CAS  Google Scholar 

Komaba H, Nakamura M, Fukagawa M (2017) Resurgence of parathyroidectomy: evidence and outcomes. Curr Opin Nephrol Hypertens 26:243

Article  PubMed  Google Scholar 

Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575–580

Article  PubMed  CAS  Google Scholar 

Nemeth EF, Heaton WH, Miller M et al (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308(2):627–635

Article  PubMed  CAS  Google Scholar 

Bover J, Ureña P, Ruiz-García C, daSilva I, Lescano P, del Carpio J, Ballarín J, Cozzolino M (2016) Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 11(1):161–174

Article  PubMed  CAS  Google Scholar 

Block GA, Martin KJ, de Francisco AL et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350(15):1516–1525

Article  PubMed  CAS  Google Scholar 

Raggi P, Chertow GM, Torres PU et al (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26(4):1327–1339

Article  PubMed  CAS  Google Scholar 

Ureña-Torres PA, Floege J, Hawley CM et al (2013) Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transpl 28(1):146–152

Article  Google Scholar 

EVOLVE Trial Investigators (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482–2494

Article  Google Scholar 

Parfrey PS, Chertow GM, Block GA et al (2013) The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab 98(12):4834–4844

Article  PubMed  CAS  Google Scholar 

Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS (2015) The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial. Clin J Am Soc Nephrol 10(5):800–807

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dufner MM, Kirchhoff P, Remy C et al (2005) The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands. Am J Physiol Gastrointest Liver Physiol 289(6):G1084–G1090

Article  PubMed  CAS  Google Scholar 

Tokunaga S, Kawata T (2021) The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs. PLoS One 16(1):e0245785

Article  PubMed  PubMed Central  CAS  Google Scholar 

Padhi D, Harris R (2009) Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 48(5):303–311

Article  PubMed  CAS  Google Scholar 

Alexander ST, Hunter T, Walter S et al (2015) Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol 88(5):853–865

Article  PubMed  CAS  Google Scholar 

Wu B, Melhem M, Subramanian R et al (2018) Clinical pharmacokinetics and pharmacodynamics of etelcalcetide, a novel calcimimetic for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. J Clin Pharmacol 58(6):717–726

Article  PubMed  CAS  Google Scholar 

Block GA, Bushinsky DA, Cunningham J et al (2017) Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 317(2):146–155

Article  PubMed  CAS  Google Scholar 

Russo D, Tripepi R, Malberti F et al (2019) Etelcalcetide in patients on hemodialysis with severe secondary hyperparathyroidism: multicenter study in real life. J Clin Med 8(7):1066

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xipell M, Montagud-Marrahi E, Rubio MV et al (2019) Improved control of secondary hyperparathyroidism in hemodialysis patients switching from oral cinacalcet to intravenous etelcalcetide, especially in nonadherent patients. Blood Purif 48(2):106–114

Article  PubMed  CAS  Google Scholar 

Arenas MD, Rodelo-Haad C, de Mier MVP, Rodriguez M (2020) Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patient’s adherent and non-adherent to oral calcimimetics. Clin Kidney J 14(3):84

Google Scholar 

Karaboyas A, Muenz D, Fuller DS et al (2022) Etelcalcetide utilization, dosing titration, and chronic kidney disease-mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients. Am J Kidney Dis 79(3):362–373

Article  PubMed  CAS  Google Scholar 

Karaboyas A, Muenz D, Hwang Y, Goodman W, Cheng S, Desai P, Fox KM, Robinson BM, Pisoni RL (2022) Etelcalcetide versus cinacalcet in hemodialysis patients in the United States: a facility calcimimetic approach to assess real-world effectiveness. Kidney Med 4(6):100475

Article  PubMed  PubMed Central  Google Scholar 

Perrone V, Dovizio M, Veronesi C, Andretta M, Bartolini F, Cavaliere A, Ferrante F, Lupi A, Pagliaro R, Pagnotta R, Palcic S, Re D, Ubertazzo L, Vercellone A, Degli EL (2022) Real-World evaluation of calcimimetics for the treatment of secondary hyperparathyroidism in chronic kidney disease, in an Italian clinical setting. Healthcare (Basel) 10(4):709

Article  PubMed  Google Scholar 

Bonn B, Masimirembwa CM, Aristei Y et al (2008) The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition. Drug Metab Dispos 36(11):2199–2210

Article  PubMed  CAS  Google Scholar 

Leach K, Gregory KJ, Kufareva I et al (2016) Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. Cell Res 26(5):574–592

Article  PubMed  PubMed Central  CAS  Google Scholar 

Miyazaki H, Ikeda Y, Sakurai O et al (2018) Discovery of evocalcet, a next generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. Bioorg Med Chem Lett 28(11):2055–2060

Article  PubMed  CAS  Google Scholar 

Fukagawa M, Shimazaki R, Akisawa T et al (2018) Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 94(4):818–825

Article  PubMed  CAS  Google Scholar 

Yokoyama K, Shimazaki R, Fukagawa M et al (2019) Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperp